As the novel coronavirus (“COVID-19”) continues to spread in the United States, health care providers are turning to the federal government for guidance and flexibilities for them to respond to the ...

As regulatory scrutiny increases and manufacturer restrictions continue to evolve, Halo 340B provides an intelligent safety net that transforms 340B management from a high-risk administrative burden ...

On October 30, HRSA announced that it had selected eight drug manufacturers to participate in its 340B Rebate Model Pilot Program, spanning 10 drugs representing a range of widely used therapies.

Hospitals are suing to block a Trump administration pilot that will allow drugmakers to issue post-sale rebates instead of upfront discounts on medications in the 340B drug discount program, arguing ...

Johnson & Johnson has informed the Health Resources and Services Administration (HRSA) that it has "no choice but to forgo implementation" of its controversial plan to swap out upfront 340B drug ...

A federal judge has, at least temporarily, nixed a longstanding restriction on whether some 340B hospitals could use group purchasing organizations to make initial purchases of covered outpatient ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

Small business owners are struggling to keep up with the rising cost of healthcare. Nearly a third have recently stopped ...

The Health Resources and Services Administration’s definition of who qualifies as a patient under the 340B drug pricing program is too narrowly defined, a federal judge ruled Nov. 7. The lawsuit was ...